Future
Medicinal
Chemistry
Research Article
part of
Future Med. Chem. (Epub ahead of print) ISSN 1756-8919 10.4155/fmc-2016-0240 © 2017 Future Science Ltd
Aim: The discovery of new generation of selective COX-2 inhibitors with potential
analgesic and anti-inflammatory activity and minimal side effects is a major interest.
Materials & methods: Novel imidazole and imidazo[1,5-a]quinazoline derivatives
were prepared and evaluated for their analgesic and anti-inflammatory activities.
COX-1/COX-2 isozyme selectivity testing and molecular docking were performed. Key
physicochemical parameters were calculated. Results: All tested compounds exhibited
significant activities compared with indomethacin as reference drug. Pharmacological
evaluation showed that compounds 3c and 14c possess promising analgesic activity,
pronouncing anti-inflammatory effect and reasonable COX-2 selectivity. Molecular
docking attributed their good activity to their hydrogen bonding interaction with
key amino acids in COX isozymes Arg120, Tyr355 and Ser530. Most compounds obeyed
‘Lipinski’s rule of five’ and possess promising pharmacokinetic properties.
Graphical abstract
3D representation showing its interaction
with COX-1 enzyme active site.
Graphical Abstract
COX-1/COX-2 Ratio 17.50
Analgesic protection 100%
% inhibition of
Anti-inflammatory activity 76.16% (2h), 78.1% (3h)
N
N
HOOC
HO
Cl
3c
First draft submitted: 22 December 2016; Accepted for publication: 15 February 2017;
Published online: 10 April 2017
Keywords: analgesic•anti-infammatory•COXinhibition•imidazole•imidazo[1,5-a]
quinazoline•Lipinski’sparameters
Relieving pain is an important target in
research as it is a very serious problem
included in most of diseases. Pain may be
physiological, neuropathic or inflammatory
due to infection or tissue damage. Gener-
ally, pain can be treated by the use of non-
steroidal anti-inflammatory drugs (NSAIDs)
or opiates [1] . Opioids are used mainly in
Synthesis and molecular docking of new
imidazoquinazolinones as analgesic agents
and selective COX-2 inhibitors
Hassanein H Hassanein
1
,
Hanan H Georgey
1
,
Marwa A Fouad*
,1
,
Ahmed M El Kerdawy
1,2
& Mona F Said
1
1
DepartmentofPharmaceutical
Chemistry,FacultyofPharmacy,Cairo
University,Cairo11562,Egypt
2
MolecularModelingUnit,Facultyof
Pharmacy,CairoUniversity,KasrEl-Aini
Street,Cairo11562,Egypt
*Authorforcorrespondence:
Tel:+201222441198
marwa.fouad@pharma.cu.edu.eg
For reprint orders, please contact reprints@future-science.com